| 10/5/2012 | CV | New Issue: Cell Therapeutics sells upsized $60 million convertible preferreds
|
| 10/4/2012 | CV | Cell Therapeutics plans $40 million convertible preferred shares
|
| 10/4/2012 | CV | Market Commentary: New Ares Capital flat after pricing at discount; WellPoint gains; NuVasive loses on hedge
|
| 8/2/2012 | CVHYPF | Cell Therapeutics files $150 million shelf for stock, debt, preferreds
|
| 12/19/2011 | CVLM | Cell Therapeutics pays $11.2 million, retires all 5.75% convertibles
|
| 10/25/2011 | CVHYPF | Cell Therapeutics files $100 million shelf for stock, debt, preferreds
|
| 5/2/2011 | CVLM | Cell Therapeutics retires 7.5% convertibles, leaving just one series
|
| 7/1/2010 | CVLM | Cell Therapeutics to retire all remaining 4% convertible notes
|
| 5/26/2010 | CVLM | Cell Therapeutics swaps stock for $1.85 million of 4% convertibles
|
| 5/20/2010 | CVLM | Cell Therapeutics agrees to exchange up to $30 million 4% convertibles
|
| 5/17/2010 | CVLM | Cell Therapeutics to issue shares in exchange for up to $30 million of 4% convertible notes
|
| 6/19/2009 | CV | Cell Therapeutics accepts $52.92 million of convertibles in exchange
|
| 6/17/2009 | CV | Cell Therapeutics holders tender 46.1% of convertibles in exchange
|
| 6/3/2009 | CV | Cell Therapeutics amends offer for convertibles to offer fixed payment
|
| 5/19/2009 | CV | Cell Therapeutics ups payment in exchange offer for up to $89.2 million of convertibles
|
| 5/12/2009 | CV | Cell Therapeutics begins exchange offer for $89.2 million convertibles in Dutch auction
|
| 5/11/2009 | CVPP | Cell Therapeutics to exchange up to $89.2 million of convertibles in modified Dutch auction
|
| 4/17/2009 | CVPP | Cell Therapeutics issues common shares for remaining preferred shares
|
| 2/5/2009 | CV | Cell Therapeutics exchanges 83% of convertible preferreds
|
| 12/5/2008 | CV | Cell Therapeutics board OKs modified Dutch auction offer for five series of convertibles
|
| 9/5/2008 | CVHY | Cell Therapeutics files $150 million stock, debt securities shelf
|
| 3/31/2008 | CVHY | Cell Therapeutics files $150 million shelf registration
|
| 3/4/2008 | CVPP | New Issue: Cell Therapeutics sells $51.66 million four-year convertibles to yield 9%, up 10%
|
| 2/13/2008 | CV | Cell Therapeutics exchanges $9.1 million convertibles for stock
|
| 12/13/2007 | CV | Cell Therapeutics issues $23.25 million 5.75% convertibles, shares in exchange for $36.1 million notes
|
| 11/26/2007 | CV | Market Commentary: Countrywide, Fannie Mae, E*Trade down as financials tumble; SunPower, Suntech Power brighten dark day
|
| 6/1/2007 | CVHY | Cell Therapeutics files $150 million shelf
|
| 8/23/2006 | CV | Market Commentary: Gateway climbs on offer; Developers REIT deal falls flat; Cell leaps on trial data; Ford picks up speed
|
| 4/25/2006 | CV | Market Commentary: Serologicals weakens on hedged basis; JetBlue, Level 3 gain on results; Dov falls on drug trial woes
|
| 4/25/2006 | BTCV | New Issue: Cell Therapeutics prices $33.2 million of 5-year convertibles at 7.5%, up 15%
|
| 4/6/2006 | BTCV | Cell Therapeutics plans $50 million to $100 million convertible sale or exchange
|
| 4/6/2006 | CV | Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
|
| 2/8/2006 | CV | Market Commentary: Citadel retraces some gains; Qwest flat but adds on hedge; MGI better; Oil States lower; Pier 1 prices
|
| 2/3/2006 | BTCV | Cell Therapeutics files $150 million debt, stock shelf
|
| 11/1/2005 | BTCV | New Issue: Cell Therapeutics $82 million five-year convertibles yield 6.75%, up 10%
|
| 11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
| 6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
| 3/7/2005 | CV | Market Commentary: Genworth synthetic coming; Cell Therapeutics dives; Celgene rises; Saks bagged up; Lions Gate higher
|
| 6/18/2003 | CV | New Issue: Cell Therapeutics downsized $75 million convertibles at 4.0% yield, up 23.5%
|
| 6/18/2003 | CV | Market Commentary: CNet pulled, other new deals sweetened; Reliant upsizes as buyers reach for a fat coupon
|
| 6/17/2003 | CV | Cell Therapeutics $100 million overnighter talked to yield 3.5-4.0%, up 25-30%
|
| 6/17/2003 | CV | Market Commentary: New deal parade marches on; Lattice reoffered at 98, still dives; secondary thin, lower
|
| 3/26/2003 | CV | Deutsche analysts say many of convertibles with worst up/down profiles have short-dated puts
|
| 2/26/2003 | CV | Market Commentary: New issues bid up in gray; Tyco's new converts gain sharply, power names dive
|
| 1/7/2003 | CV | Market Commentary: Heavy trading on Tyco deal; InterMune dives, techs and telecoms soar, power mixed
|
| 12/19/2002 | CV | Market Commentary: Market settles back into slow, holiday-like mode
|
| 12/18/2002 | CV | Cell Therapeutics says $145.36 million convertibles tendered in exchange
|
| 12/17/2002 | CV | Market Commentary: Market remains quiet as two small deals price, stocks slip
|
| 11/20/2002 | CV | Market Commentary: Xcel's new deal screams higher while others edge up, languish
|
| 11/19/2002 | CV | Cell Therapeutics offers to exchange convertibles for fewer notes with lower conversion price
|
| 9/4/2002 | CV | Market Commentary: Market tone improves but still patchy; Symantec, Calpine gain
|
| 6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
| 5/20/2002 | CV | Market Commentary: Buyers emerge for downtrodden Adelphia, Lucent, energy traders; biotechs fall amid profit taking
|
| 12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|
| 11/27/2001 | CV | Market Commentary: Convertible market seen flat on heavy trading from high volatility
|
